Intellia Therapeutics Inc buy Royal Bank of Canada
Start price
10.11.23
/
50%
€22.58
Target price
10.11.24
€65.49
Performance (%)
-10.94%
Price
28.08.24
€20.11
Summary
This prediction is currently active. The price of Intellia Therapeutics Inc has decreased since the start of the prediction. Compared to the start price this results in a performance of -10.94%. This prediction currently runs until 10.11.24. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Intellia Therapeutics Inc | -5.007% | -5.007% |
iShares Core DAX® | 1.743% | 1.903% |
iShares Nasdaq 100 | -2.088% | -0.640% |
iShares Nikkei 225® | 1.306% | 4.161% |
iShares S&P 500 | -0.093% | 0.169% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Royal Bank of Canada from $80.00 to $70.00. They now have an "outperform" rating on the stock.
Ratings data for NTLA provided by MarketBeat
Stopped prediction by Royal_Bank_of_Canada for Intellia Therapeutics Inc
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€19.65
09.08.24
09.08.24
€49.44
09.08.25
09.08.25
2.37%
28.08.24
28.08.24